"Donald Trump has warned he is likely to impose tariffs of 25 per cent or more on pharmaceutical imports to the United States, sparking a fresh trade threat for Australia’s multi-billion dollar drug and medication manufacturing industry."
Quote today from article in The Australian.
Implications for Neuren?
Our current arrangement with Acadia would seem to be exempt.
Developing NNZ-2591 in-house might become problematic although it might encourage a Nasdaq listing.
I'm yearning for a t/o - my mind is frazzled.
"Donald Trump has warned he is likely to impose tariffs of 25...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$17.16 |
Change
0.530(3.19%) |
Mkt cap ! $2.167B | |||
| Open | High | Low | Value | Volume |
| $16.80 | $17.34 | $16.63 | $4.081M | 240.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 127 | $17.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.17 | 58 | 5 |
View Market Depth
| Last trade - 13.05pm 31/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |